0001209191-19-029148.txt : 20190510
0001209191-19-029148.hdr.sgml : 20190510
20190510201002
ACCESSION NUMBER: 0001209191-19-029148
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190508
FILED AS OF DATE: 20190510
DATE AS OF CHANGE: 20190510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaughn James J
CENTRAL INDEX KEY: 0001649689
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 19816593
MAIL ADDRESS:
STREET 1: C/O GENOMIC HEALTH, INC.
STREET 2: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-08
0
0001131324
GENOMIC HEALTH INC
GHDX
0001649689
Vaughn James J
301 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
Chief Commercial Officer
Common Stock
2019-05-08
4
M
0
3000
31.12
A
26164
D
Common Stock
2019-05-08
4
M
0
1500
31.12
A
27664
D
Common Stock
2019-05-08
4
S
0
600
57.0817
D
27064
D
Common Stock
2019-05-08
4
S
0
1258
57.8881
D
25806
D
Common Stock
2019-05-08
4
S
0
1142
58.9126
D
24664
D
Common Stock
2019-05-08
4
S
0
358
57.1451
D
24306
D
Common Stock
2019-05-08
4
S
0
542
57.7309
D
23764
D
Common Stock
2019-05-08
4
S
0
600
58.8583
D
23164
D
Common Stock
2019-05-08
4
S
0
700
57.1486
D
22464
D
Common Stock
2019-05-08
4
S
0
1044
57.8249
D
21420
D
Common Stock
2019-05-08
4
S
0
1000
58.943
D
20420
D
Employee Stock Option (right to buy) Holding
31.12
2019-05-08
4
M
0
3000
0.00
D
2025-02-13
Common Stock
3000
16897
D
Employee Stock Option (right to buy) Holding
31.12
2019-05-08
4
M
0
1500
0.00
D
2025-02-13
Common Stock
1500
15397
D
Includes an aggregate of 11,281 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $56.57 to $57.53.
Represents weighted average sale price. Actual sale prices ranged from $57.65 to $58.60.
Represents weighted average sale price. Actual sale prices ranged from $58.65 to $59.44.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 11, 2019.
Represents weighted average sale price. Actual sale prices ranged from $56.55 to $57.53.
Represents weighted average sale price. Actual sale prices ranged from $57.58 to $57.98.
Represents weighted average sale price. Actual sale prices ranged from $58.61 to $59.20.
Represents weighted average sale price. Actual sale prices ranged from $56.57 to $57.54.
Represents weighted average sale price. Actual sale prices ranged from $57.60 to $58.26.
Represents weighted average sale price. Actual sale prices ranged from $58.60 to $59.44.
The option became exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.
/s/ Jason W. Radford, Attorney-in-fact
2019-05-10